Introduction {#Sec1}
============

Since December 2019, respiratory tract infection cases caused by virus occurred in Wuhan, Hubei Province, China \[[@CR1], [@CR2]\]. At first, a majority of cases was clustered around the local Huanan Seafood Wholesale Market, where wild animals were illegally sold. Then, the disease had rapidly spread from Wuhan to all over the China and to many foreign countries \[[@CR3]\]. On Jan 7, the responsible novel coronavirus was identified by the Chinese Center for Disease Control and Prevention (CDC), and was subsequently named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously known as 2019-nCoV) by WHO, and pneumonia caused by 2019-nCoV was named COVID-19 \[[@CR4]\]. The emerging virus was rapidly characterized as a novel member of the coronavirus family \[[@CR5]\].

Some case series have demonstrated the clinical characteristics and epidemiological features of COVID-19 \[[@CR6]--[@CR8]\]. Clinical manifestations caused by SARS-CoV-2 varied, encompassing asymptomatic infection, pneumonia, acute respiratory distress syndrome (ARDS) and even death \[[@CR6]--[@CR8]\]. The mortality of patients with severe illness is extremely high \[[@CR9]\]. However, risk factors leading to deterioration and poor outcome in severe COVID-19 patients have not been well described. In the present study, the clinical data of 1190 COVID-19 patients admitted in Wuhan Infectious Disease Hospital (discharge or death) were collected to analyze the clinical features and potential predictors for deterioration and/or death in COVID-19 patients. We paid close attention to the issues as below: first, comparing the clinical features between different severity and outcomes, shedding light on the risk factors for mortality and progression prediction; second, comparing the time interval to respiratory supports between survivors and non-survivors, exploring the preferable respiratory support to decrease mortality.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

This was a single-center, retrospective, observational study conducted from December 29, 2019, to February 28, 2020. A total of 1190 adult (18--94 years) patients with confirmed COVID-19 from Wuhan Infectious Disease Hospital were enrolled. All patients with confirmed COVID-19 enrolled in this study were diagnosed according to World Health Organization (WHO) interim guidance \[[@CR10]\]. This study was approved by the Medicine Institutional Review Board of Wuhan Infectious Disease Hospital (KY-2020-03.01). Informed consents were waived from study participants.

Data collection {#Sec4}
---------------

The epidemiological, demographic, clinical, laboratory data were extracted mostly on admission from medical records. The collected information included age, sex, comorbidities, exposure history, oxygen support during hospitalization (nasal cannula, non-invasive mechanical ventilation, invasive mechanical ventilation or invasive medical ventilation with extracorporeal membrane oxygenation \[ECMO\]), symptoms onset on admission, vital signs, serum laboratory tests (including blood routine tests, blood chemical variables, procalcitonin, coagulation function tests), chest X-ray and computed tomographic (CT) scans, therapeutic strategy during hospitalization (antivirus treatment \[ganciclovir, oseltamivir, arbidol, lopinavir and ritonavir, interferon\], antibiotics \[cefprozil, ceftriaxone, cefoperazone--sulbactam, piperacillin--tazobactam, biapenem, meropenem, vancomycin, linezolid, sulfamethoxazole, levofloxacin and moxifloxacin\], glucocorticoids) and outcomes. Throat-swab specimens from patients with history of epidemiology and characteristics of virus pneumonia in chest CT or X-ray, were obtained. The time interval between two specimens was at least 24 h apart. Detection of 2019-nCoV nucleic acid was performed at the CDC before January 23, 2020, and subsequently at designated hospitals (Chinese Academy of Medical Sciences, Academy of Military Medical Sciences, and Wuhan Institute of Virology of the Chinese Academy of Sciences) as previously described. Patients with at least two consecutive times of positive results from high-throughput sequencing or real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swab specimens were confirmed with COVID-19. The included patients in the current study were all with determined laboratory results.

Definition {#Sec5}
----------

COVID-19 diagnosis was according to WHO interim guidance \[[@CR10]\]. The severity of COVID-19 was classified into mild, moderate, severe and critical type. The classification was assessed according to the diagnosis and treatment of COVID-19 guidelines (sixth version) published by the National Health Commission of China \[[@CR11]\] (Additional file [1](#MOESM1){ref-type="media"}). Progressors were defined as mild or moderate patients who developed severe or critically illness during hospitalization. Non-progressors were defined as mild or moderate patients who never developed severe or critically illness during hospitalization. The disease onset was defined as the day when related symptoms first appeared.

Endpoints {#Sec6}
---------

In the present study, the endpoints included in-hospital deterioration and/or death among those with severe disease. The time intervals from symptom onset or admission to high-flow nasal oxygen, non-invasive mechanical ventilation (NIV), invasive mechanical ventilation (IMV), extracorporeal membrane oxygenation (ECMO) were also recorded.

Statistical analysis {#Sec7}
--------------------

Statistical analyses were performed using SPSS (version 24.0, SPSS Inc., Chicago, IL, USA) and SAS (version 9.3, SAS Institute, Cary, NC). Continuously normally distributed data were reported as mean (deviation) and compared using Student's t test. Continuously non-normally distributed data were reported as median (interquartile range) and compared using Wilcoxon rank-sum test. Categorical data were presented as n (percentage) and compared using Chi-square test, Fisher's exact test, and Cochran--Mantel--Haenszel test, as appropriate.

The potential risk factors for in-hospital deterioration (from not severe to severe disease) and death particularly in severe COVID-19 patients were determined using univariable and multivariable logistic regression model and displayed as odds ratio (OR) and 95% confidence interval (CI). Variables with a *p* value of 0.05 or less in the univariable analysis were considered as candidate variables in the multivariable analysis. Due to the statistical rule that the ratio of events and per variable should be ten or more, only 16 variables were finally selected based on the clinical importance. To exclude the possible bias introduced by missing data, we performed a sensitivity analysis using multiple imputations to account for missing data. Five imputations of complete data were generated and refitted into the multivariable logistic regression to test whether a selected variable remained to be the independent factor for illness deterioration and in-hospital mortality.

To evaluate the effects of anti-viral agents on clinical outcomes, we compared the difference of mortality and median survival time between patients who received or not received the anti-viral agents as follows: oseltamivir, ganciclovir, lopinavir--ritonavir, γ-interferon, arbidol. Kaplan--Meier curves and log-rank test were also used for survival analyses. To explore whether a specific anti-viral agent was independently associated with prolonged survival, we used multivariable Cox proportional-hazards model to compute the hazard ratio (HR) for each anti-viral agent by incorporating the same co-variables used in the multivariable logistic regression model for adjustment. A two-sided *p* value less than 0.05 was defined as statistically significant for all the analyses.

Results {#Sec8}
=======

Demographic and clinical characteristics {#Sec9}
----------------------------------------

1190 patients with confirmed COVID-19 were recorded in Wuhan Infectious Disease Hospital during the study period, including 555 (46.6%) females and 635 males (53.4%), with an average age of 57 years (47--67). The flowchart of the current study is shown in Fig. [1](#Fig1){ref-type="fig"}. Demographic and clinical details were obtained for all the patients (Table [1](#Tab1){ref-type="table"}). In total, 131 (11.4%) patients had a history of exposure to the Huanan seafood market, 132 (11.2%) were household clustered, and 16 (1.4%) were medical staff. The most commonly self-reported symptoms on admission were fever (*n* = 971, 81.9%), cough (*n* = 879, 74.2%), dyspnea (*n* = 548, 46.3%), fatigue (*n* = 434, 36.7%) and sputum production (*n* = 417, 35.2%). 441 (37.1%). Patients had comorbidities, including chronic obstructive pulmonary disease (*n* = 22, 1.9%), diabetes (*n* = 144, 12.2%), hypertension (*n* = 308, 26.1%), chronic cardiac disease (*n* = 86, 7.3%), chronic kidney disease (*n* = 30, 2.6%), chronic liver disease (*n* = 40, 3.4%), stroke (*n* = 39, 3.3%), malignancy (*n* = 34, 2.9%), immunosuppression (*n* = 24, 2.0%), and tuberculosis (*n* = 15, 1.3%).Fig. 1Flowchart in the present studyTable 1Clinical characteristics, radiographic, laboratory results of patients with COVID-19All patients (*n* = 1190)Survivor (*n* = 1033)Non-survivor (*n* = 157)*p* valueAgeMedian (IQR), year57 (47, 67)56 (46, 65)69 (62, 77)\< 0.0001Sex, *n* (%) Female555 (46.6)498 (48.2)57 (36.3)0.0053 Male635 (53.4)535 (51.8)100 (63.7)Smoking, *n* (%)45 (4.5)40 (4.6)5 (3.8)1Drinking, *n* (%)48 (4.6)43 (4.7)5 (3.9)0.6901Epidemic disease history, *n* (%) Influenza A  Negative1131 (96.5)987 (96.7)144 (94.8)0.4308  Positive19 (1.6)15 (1.5)4 (2.6)  Unchecked or unknown22 (1.9)18 (1.8)4 (2.6) Influenza B  Negative1133 (96.6)990 (97.0)143 (94.1)0.1257  Positive18 (1.5)13 (1.2)5 (3.3)  Unchecked or unknown22 (1.9)18 (1.8)4 (2.6)Exposure history, *n* (%) Huanan seafood market131 (11.4)125 (12.5)6 (4.1)0.0028 Wuhan exposure1119 (94.7)968 (94.2)151 (98.1)0.0451 Other parts of Hubei56 (5.0)54 (5.5)2 (1.4)0.0373 Contact with wildlife17 (1.5)17 (1.8)0 (0.0)0.2238 Medical staff16 (1.4)16 (1.6)0 (0.0)0.2446 Clustered cases132 (11.2)118 (11.5)14 (9.2)0.6726Any comorbidity, *n* (%)441 (37.1%)345 (33.4%)96 (61.15%)\< 0.0001 Chronic obstructive pulmonary disease22 (1.9)14 (1.4)8 (5.3)1 Diabetes144 (12.2)105 (10.2)39 (25.5)\< 0.0001 Hypertension308 (26.1)244 (23.8)64 (41.8)\< 0.0001 Chronic cardiac disease86 (7.3)61 (6.0)25 (16.3)\< 0.0001 Chronic kidney disease30 (2.6)24 (2.4)6 (3.9)0.38 Chronic liver disease40 (3.4)32 (3.1)8 (5.2)0.1779 Stroke39 (3.3)28 (2.7)11 (7.2)0.0041 Malignancy34 (2.9)26 (2.5)8 (5.2)0.1115 Immunosuppression24 (2.0)15 (1.5)9 (5.9)0.0009 Tuberculosis15 (1.3)10 (1.4)5 (3.3)0.0475Signs and symptoms at admission, *n* (%) Fever971 (81.9)834 (80.9)137 (89.0)0.0152 Median highest temperature (IQR), °C38.5 (38.0, 39.0)38.5 (38.0, 39.0)38.5 (38.0, 39.0)0.0233 Nasal congestion11 (0.9)8 (0.8)3 (2.0)1 Nasal discharges16 (1.4)13 (1.3)3 (2.0)0.7521 Sneeze5 (0.4)4 (0.4)1 (0.7)0.5019 Sore throat39 (3.3)36 (3.5)3 (2.0)0.3171 Cough879 (74.2)751 (72.8)128 (83.7)0.0041 Sputum production417 (35.2)352 (34.1)65 (42.5)0.0438 Dyspnoea548 (46.3)439 (42.6)109 (71.2)\< 0.0001 Chest pain62 (5.3)56 (5.5)6 (3.9)0.427 Hemoptysis14 (1.2)11 (1.1)3 (2.0)0.5846 Headache61 (5.2)59 (5.8)2 (1.3)0.0204 Myalgia133 (11.3)116 (11.3)17 (11.1)0.937 Fatigue434 (36.7)369 (35.9)65 (42.5)0.1128 Gastrointestinal symptoms214 (18.2)189 (18.4)25 (16.3)0.5333 Eye symptoms23 (2.0)22 (2.2)1 (0.7)0.3502 Ronchi57 (4.8)47 (4.6)10 (6.5)0.2953 Crackles170 (14.4)143 (13.9)27 (17.5)0.2265 Systolic pressure  Median (IQR), mmHg122 (111, 135)122 (110, 134)130.5 (117, 144)0.0002 Diastolic pressure  Median (IQR), mmHg80 (72, 87)80 (73, 87)80 (72, 87)0.0944 Heart rate  Median (IQR), bpm86 (79, 96)86 (78, 96)89 (82, 102)\< 0.0001 Respiratory rate  Median (IQR), bpm22 (20, 25)21 (20, 25)23 (20, 28)0.9936SOFA3 (1, 5)2 (1, 4)10 (6, 18)\< 0.0001APACHEII3 (1, 6)3 (1, 5)10.5 (8, 17)\< 0.0001Laboratory findings Leucocytes (IQR-10^9^/L)6.3 (4.6, 9.1)6.0 (4.5, 8.1)15.5 (8.9, 21.9)\< 0.0001 Distribution, *n* (%)  \< 4185 (16.1)171 (16.9)14 (10.1)\< 0.0001  4--10726 (63.0)702 (69.2)24 (17.3)  \> 10242 (21.0)141 (13.9)101 (72.6) Neutrophils (IQR-10^9^/L)4.4 (2.9, 7.3)4.1 (2.8, 6.2)14.7 (9.9, 20.3)\< 0.0001 Distribution, *n* (%)  \< 1.865 (5.8)61 (6.1)4 (3.1)\< 0.0001  1.8--6.3715 (63.2)702 (70.2)13 (10.0)  \> 6.3351 (31.0)237 (23.7)114 (87.0) Lymphocytes (IQR-10^9^/L)1.2 (0.7, 1.6)1.2 (0.9, 1.6)0.5 (0.3, 0.9)\< 0.0001 Distribution, *n* (%)  \< 0.8315 (28.0)221 (22.2)94 (72.9)\< 0.0001  ≥ 0.8809 (72.0)774 (77.8)35 (27.1) CD3 (IQR-/μL)618 (427, 964)647 (468, 991)367 (267, 409)\< 0.0001 CD4 (IQR-/μL)366 (242, 594)388 (275, 645)211 (275, 645)\< 0.0001 CD8 (IQR-/μL)235 (138, 337)242 (156, 356)129 (87, 144)\< 0.0001 Hemoglobin (IQR-g/L)120 (109.0, 130.0)120 (110.0, 130.0)120 (103.0, 133.0)0.4723 Distribution, *n* (%)  ≤ 9054 (4.7)7 (3.7)17 (12.8)\< 0.0001  \> 901092 (95.3)976 (96.3)116 (87.3) Platelets (IQR-10^9^/L)193 (143.0, 250.0)201 (154.0, 256.0)90.5 (50.0, 165.0)\< 0.0001 Distribution, *n* (%)  \< 100122 (10.6)49 (4.8)73 (52.9)\< 0.0001  ≥ 1001029 (89.4)964 (95.2)65 (47.1) Prothrombin time (IQR-s)11.5 (10.7, 12.6)11.4 (10.6, 12.3)14 (12.4, 17.5)\< 0.0001 Distribution, *n* (%)  \< 10.5201 (18.0)197 (20.0)4 (3.0)\< 0.0001  10.5--13.5763 (68.2)711 (72.3)52 (38.8)  \> 13.5154 (13.8)76 (7.7)78 (58.2) Activated-partial thromboplastin time (IQR-s)27.7 (24.3, 32.5)27.2 (24.2, 31.8)33.4 (26.1, 38.9)\< 0.0001 Distribution, *n* (%)  \< 2168 (6.1)61 (6.2)7 (5.4)\< 0.0001  21--37927 (83.4)847 (86.3)80 (62.0)  \> 37116 (10.4)74 (7.5)42 (32.6) Thrombin time (IQR, s)17.9 (16.7, 20.6)17.8 (16.7, 20.4)18.4 (17.1, 23.0)0.0054 Distribution, *n* (%)  \< 138 (0.7)8 (0.8)0 (0.0)0.0321  13--21842 (75.9)753 (76.7)89 (69.5)  \> 21260 (23.4)221 (22.5)39 (30.5) D-dimer (IQR, μg/mL)0.9 (0.4, 2.5)0.8 (0.4, 1.6)17.8 (4.5, 56.5)\< 0.0001 Distribution, *n* (%)  ≤ 0.5323 (29.6)319 (33.2)4 (3.1)\< 0.0001  0.5--1279 (25.6)270 (28.1)9 (6.9)  \> 1489 (44.8)371 (38.7)118 (90.9) Total bilirubin (IQR, μmol/L)13 (10.1, 17.7)12.4 (9.8, 16.1)24.9 (16.6, 36.1)\< 0.0001 Distribution, *n* (%)  ≤ 261005 (90.0)932 (94.8)73 (54.5)\< 0.0001  \> 26112 (10.0)51 (5.2)61 (45.5) Alanine aminotransferase (IQR-U/L)42 (25.0, 66.0)40 (24.0, 62.0)47 (31.0, 84.0)0.0003 Distribution, *n* (%)  ≤ 40559 (48.8)508 (50.2)51 (37.8)0.0065  \> 40587 (51.2)503 (49.8)84 (62.2) Aspartate aminotransferase (IQR-U/L)35 (26.0, 51.0)33 (25.0, 46.0)58 (44.0, 109.0)\< 0.0001 Distribution, *n* (%)  ≤ 40702 (61.2)680 (67.3)22 (16.1)\< 0.0001  \> 40445 (38.8)330 (32.7)115 (83.9) Albumin (IQR, g/L)31.3 (28.0, 34.7)32 (29.0, 35.2)26.15 (24.3, 28.3)\< 0.0001 Distribution, *n* (%)  \< 401106 (96.2)966 (95.6)140 (100.0)0.0144  40--5541 (3.6)41 (4.1)0 (0.0)  \> 553 (0.3)3 (0.3)0 (0.0) Serum prealbumin (IQR-g/L)125 (80.0, 187.0)137 (91.0, 194.0)48.5 (29.5, 75.0)\< 0.0001 Distribution, *n* (%)  \< 200874 (79.2)748 (76.7)126 (98.4)\< 0.0001  200--430229 (20.8)227 (23.3)2 (1.6) Blood urea nitrogen (IQR-mmol/L)5.2 (4.1, 6.8)4.97 (4.0, 6.2)13.2 (7.7, 20.3)\< 0.0001 Distribution, *n* (%)  \< 3.181 (7.1)81 (8.0)0 (0.0)\< 0.0001  3.1--8865 (75.7)827 (82.1)38 (28.4)  \> 8196 (17.2)100 (9.9)96 (71.6) Serum creatinine (IQR, μmol/L)72.6 (59.6, 88.6)71.5 (59.0, 84.3)107.8 (69.2, 196.7)\<0.0001 Distribution, *n* (%)  \> 13384 (7.4)32 (3.2)52 (39.4)\< 0.0001  ≤ 1331051 (92.6)971 (96.8)80 (60.6) Creatine kinase (IQR-U/L)78 (51.0, 151.0)73 (49.0, 132.5)240 (101.0, 553.0)\< 0.0001 Distribution, *n* (%)  \< 50243 (23.7)236 (25.7)7 (6.6)\< 0.0001  50--310676 (65.9)619 (67.3)57 (53.8)  \> 310107 (10.4)65 (7.0)42 (39.6) Creatine kinase isoenzyme MB (IQR-U/L)14 (10.0, 18.0)13 (10.0, 17.0)24 (18.0, 47.0)\< 0.0001 Distribution, *n* (%)  ≤ 24960 (88.4)896 (93.3)64 (50.8)\< 0.0001  \> 24126 (11.6)64 (6.7)62 (49.2) C-reactive protein (IQR, mg/L)30.1 (5.7, 92.0)22.5 (4.3, 67.2)160 (124.2, 177.1)\< 0.0001 Distribution, *n* (%)  ≤ 6.9290 (28.4)287 (32.1)3 (2.3)\< 0.0001  \> 6.9731 (71.6)606 (67.9)125 (97.7) Serum amyloid protein A (IQR-mg/L)190.8 (34.3, 275.9)178.6 (25.6, 270.3)260.1 (188.9, 284.0)\< 0.0001 Distribution, *n* (%)  ≤ 10151 (15.8)149 (17.5)2 (1.9)\< 0.0001  \> 10805 (84.2)702 (82.5)103 (98.1) Serum ferritin (IQR-ng/mL)406.1 (137.2, 800.8)384.8 (146.0, 711.8)616.6 (38.7, 2000.0)0.0099 Distribution, *n* (%)  \< 21.836 (4.7)32 (4.9)4 (3.6)0.7535  21.8--274.6263 (34.2)224 (34.1)39 (34.8)  \> 274.6470 (61.1)401 (61.0)69 (61.6) Interleukin-6 (IQR-pg/mL)14.45 (8.0, 416.0)13.2 (7.7, 366.2)31.9 (11.1, 1487.0)\< 0.0001 Distribution, *n* (%)  ≤ 728 (3.4)25 (3.5)3 (2.8)0.909  \> 7789 (96.6)684 (96.5)105 (97.2)Radiologic findings Abnormalities, *n* (%) Ground-glass opacity1027 (92.3)910 (92.3)117 (92.1)0.9474 Pulmonary consolidation194 (17.4)155 (15.7)39 (30.7)\< 0.0001 Pulmonary interstitial abnormalities700 (63.0)609 (61.8)91 (71.7)0.0309 Pneumothorax31 (2.8)24 (2.4)7 (5.5)0.0901 Pleural effusion49 (4.4)43 (4.4)6 (4.7)0.851*SOFA* Sequential Organ Failure Assessment, *APACHEII* Acute Physiology and Chronic Health Evaluation II, *ICU* intensive care unit, *MV* mechanical ventilation

On admission, the conditions of most patients (1102, 92.6%) were not severe, of whom 261 (22.7%) patients progressed into severe disease after admission (median 12 days, IQR 2--15 days). Compared with non-progressors, patients that progressed into a severe disease were older (62 vs. 55 year, *p *\< 0.0001) and more male (60.1% vs. 51.0%, *p *= 0.0097), had more comorbidities such as diabetes (16.5% vs. 9.8%, *p *= 0.0033), hypertension (29.7% vs. 22.6%, *p *= 0.0208), stroke (7.3% vs. 2.2%, *p *= 0.0001), malignancy (4.7% vs. 2.0%, *p *= 0.0214) and immunosuppression (4.7% vs. 0.8%, *p *= 0.0001), and showed more severe initial symptoms, such as dyspnea (60.1% vs. 39.7%, *p *\< 0.0001) and higher heart rate (89 vs. 85 bpm, *p *= 0.0002) (Table [2](#Tab2){ref-type="table"}).Table 2Treatments and clinical outcomes of patients with COVID-19All patients (*n* = 1190)Survivor (*n* = 1033)Non-survivor (*n* = 157)*p* valueTreatments, *n* (%) Antibiotic977 (87.7)859 (87.0)118 (92.9)0.0575 Antifungal50 (4.5)35 (3.6)15 (11.8)\< 0.0001 Antiviral681 (61.1)626 (63.4)55 (43.3)\< 0.0001 Glucocorticoids289(25.9)213 (21.6)76 (59.8)\< 0.0001 Oxygen therapy, *n* (%)\< 0.0001  None203 (17.1)203 (19.7)0 (0.0)  Nasal cannula792(66.6)776 (75.1)16(10.2)  Mask oxygen27 (2.3)19 (1.9)7 (4.5)  High-flow nasal cannula60 (5.0)24 (2.3)36 (22.9)  Non-invasive mechanical ventilation62 (5.2)4 (0.4)58 (36.9)  Invasive mechanical ventilation42 (3.5)6 (0.6)36 (22.9)  ECMO4(0.3)04 (2.6)Outcomes Duration of MV (IQR), days5 (2.0, 8.0)6 (5.0, 9.0)4 (2.0,8.0)0.1563 Duration of ICU stay (IQR), days6 (3.0, 10.5)7 (4.0, 11.0)5 (2.0, 9.0)0.0522 Duration of in-hospital stay (IQR), days11 (7.0, 14.5)11 (8.0, 15.0)8 (4.0, 12.0)\< 0.0001 In-hospital mortality, *n* (%)157 (13.2)0 (0.0)157 (100.0)\< 0.0001*ECMO* extracorporeal membrane oxygenation, *ICU* intensive care unit, *MV* mechanical ventilation

A total of 349 severe patients were found including 88 patients who were severe on admission and 261 patients who had an initial not severe disease that progressed to a severe disease during their hospital stay. There were 157 (45.0%) deaths among the 349 severe patients. Non-survivors were older than in survivors (69 vs. 57 year, *p *\< 0.0001). There were more comorbidities including diabetes (25.5% vs. 12.2%, *p *= 0.0015), hypertension (41.8% vs. 29.0%, *p *= 0.0127) and chronic cardiac disease (16.3% vs. 6.3%, *p *= 0.0029) in the non-survivor group than in the survivor group. The major in-hospital complication rates were higher in the non-survivor group than in the survivor group (Additional file [2](#MOESM2){ref-type="media"}: Table S1). Compared with survivors, non-survivors presented with more dyspnea (71.2% vs. 55.2%, *p *= 0.0023) on admission (Table [3](#Tab3){ref-type="table"}).Table 3Clinical characteristics, radiographic, laboratory results of the study patientsNot severe patients at admission **(***n* = 1102)Non-progressors (*n* = 841)Progressors (*n* = 261)*p* valueSevere patients (*n* = 349)Survivor (*n* = 192)Non-survivor (*n* = 157)*p* valueAge Median (IQR), year56 (46, 66)55 (45, 65)62 (52, 70)\< 0.000163 (53, 72)57 (48, 66)69 (62, 77)\< 0.0001 Sex, *n* (%)  Female516 (46.8)412 (49.0)104 (39.9)0.0097143 (41.0)86 (44.8)57 (36.3)0.1088  Male586 (53.2)429 (51.0)157 (60.1)206 (59.0)106 (55.2)100 (63.7)Smoking, *n* (%)40 (4.3)25 (3.5)15 (7.2)120 (7.0)15 (9.9)5 (3.8)1Drinking, *n* (%)44 (4.6)25 (3.3)19 (8.8)0.000623 (7.9)18 (11.0)5 (3.9)0.0251Epidemic disease history, *n* (%) Influenza A  Negative1045 (96.3)799 (96.3)246 (96.5)0.4315332 (97.1)188 (98.9)144 (94.8)0.0421  Positive19 (1.8)13 (1.6)6 (2.3)6 (1.7)2 (1.1)4 (2.6)  Unchecked or unknown21 (1.9)18 (2.1)3 (1.2)4 (1.2)0 (0.00)4 (2.6) Influenza B  Negative1048 (96.5)800 (96.3)248 (97.3)0.6044333 (97.4)190 (100.0)143 (94.1)0.0032  Positive17 (1.6)13 (1.5)4 (1.6)5 (1.5)0 (0.0)5 (3.3)  Unchecked or unknown21 (1.9)18 (2.2)3 (1.1)4 (1.1)0 (0.0)4 (2.6)Exposure history, *n* (%) Huanan seafood market126 (11.9)96 (11.8)30 (12.2)0.849935 (10.5)29 (15.7)6 (4.1)0.0006 Wuhan exposure1032 (94.3)788 (94.0)244 (95.3)0.4385331 (96.2)180 (94.7)151 (98.1)0.1089 Other parts of Hubei55 (5.2)44 (5.4)11 (4.6)0.612112 (3.8)10 (5.7)2 (1.4)0.0458 Contact with wildlife17 (1.6)10 (1.2)7 (3.0)0.11697 (2.2)7 (4.0)0 (0.0)0.0404 Medical staff16 (1.5)16 (1.9)0 (0.0)0.06080 (0.0)0 (0.0)0 (0.0)1 Clustered cases125 (11.5)88 (10.6)37 (14.5)0.159744 (12.8)30 (15.8)14 (9.2)0.1736Any comorbidity, *n* (%)383 (34.8)265 (31.5)118 (45.2)\< 0.0001176 (50.4)80 (41.7)96 (61.2)0.0003 Chronic obstructive pulmonary disease18 (1.7)9 (1.1)9 (3.6)0.211713 (3.8)5 (2.7)8 (5.3)1 Diabetes124 (11.4)82 (9.8)42 (16.5)0.003362 (18.1)23 (12.2)39 (25.5)0.0015 Hypertension265 (24.3)189 (22.6)76 (29.7)0.0208119 (34.7)55 (29.0)64 (41.8)0.0127 Chronic cardiac disease70 (6.4)49 (5.9)21 (8.2)0.182337 (10.8)12 (6.3)25 (16.3)0.0029 Chronic kidney disease29 (2.7)20 (2.4)9 (3.5)0.332610 (2.9)4 (2.1)6 (3.9)0.5022 Chronic liver disease37 (3.4)28 (3.4)9 (3.5)0.916512 (3.5)4 (2.1)8 (5.2)0.1132 Stroke36 (3.3)18 (2.2)18 (7.3)0.000121 (6.1)10 (5.3)11 (7.2)0.4595 Malignancy29 (2.7)17 (2.0)12 (4.7)0.021417 (5.0)9 (4.7)8 (5.2)0.8347 Immunosuppression19 (1.8)7 (0.8)12 (4.7)0.000117 (5.0)8 (4.2)9 (5.9)0.4695 Tuberculosis14 (1.3)8 (1.0)6 (2.4)0.15897 (2.1)2 (1.1)5 (3.3)0.2858Signs and symptoms at admission, *n* (%) Fever889 (81.0)671 (80.0)218 (84.2)0.1329300 (86.7)163 (84.9)137 (89.0)0.2684 Median highest temperature (IQR) °C38.5 (38.0, 39.0)38.4 (38.0, 39.0)38.55 (38.0, 39.0)0.454938.5 (38.0, 39.0)38.5 (38.0, 39.0)38.5 (38.0, 39.0)0.0554 Nasal congestion11 (1.0)5 (0.6)6 (2.3)16 (1.7)3 (1.6)3 (2.0)1 Nasal discharges16 (1.5)10 (1.2)6 (2.3)0.3096 (1.7)3 (1.6)3 (2.0)1 Sneeze5 (0.5)2 (0.2)3 (1.2)0.16463 (0.9)2 (1.0)1 (0.7)1 Sore throat36 (3.3)31 (3.7)5 (1.9)0.16118 (2.3)5 (2.6)3 (2.0)0.9725 Cough810 (73.8)600 (71.4)210 (81.4)0.0015279 (80.9)151 (78.7)128 (83.7)0.2394 Sputum production391 (35.6)282 (33.6)109 (42.3)0.0113135 (39.1)70 (36.5)65 (42.5)0.2546 Dyspnoea488 (44.5)333 (39.7)155 (60.1)\< 0.0001215 (62.3)106 (55.2)109 (71.2)0.0023 Chest pain57 (5.2)46 (5.5)11 (4.3)0.429416 (4.6)10 (5.2)6 (3.9)0.5723 Hemoptysis11 (1.0)8 (1.0)3 (1.2)16 (1.7)3 (1.6)3 (2.0)1 Headache60 (5.5)52 (6.3)8 (3.1)0.05279 (2.6)7 (3.7)2 (1.3)0.3106 Myalgia126 (11.6)88 (10.6)38 (14.7)0.068445 (13.0)28 (14.6)17 (11.1)0.3414 Fatigue397 (36.3)298 (35.6)99 (38.5)0.3878136 (39.5)71 (37.2)65 (42.5)0.3167 Gastrointestinal symptoms200 (18.3)163 (19.5)37 (14.3)0.05951 (14.8)26 (13.5)25 (16.3)0.4669 Eye symptoms23 (2.1)16 (1.9)7 (2.7)0.4427 (2.0)6 (3.1)1 (0.7)0.2175 Rhonchi51 (4.6)33 (3.9)18 (7.0)0.043824 (6.9)14 (7.3)10 (6.5)0.7715 Crackles150 (13.7)111 (13.2)39 (15.1)0.45459 (17.1)32 (16.7)27 (17.5)0.8315Systolic pressure Median (IQR), mmHg122 (110, 134)121 (110, 133)123 (112, 136)0.2233126 (115, 139)123 (112, 136)130.5 (117, 144)0.0201Diastolic pressure Median (IQR), mmHg80 (72, 87)80 (72, 88)80 (72, 87)0.17380 (73, 87)80 (75, 87)80 (72, 87)0.2204Heart rate Median (IQR), bpm86 (79, 96)85 (78, 95)89 (80, 100)0.000289 (80, 100)88 (80, 98)89 (82, 102)0.1859Respiratory rate Median (IQR), bpm21 (20, 25)21 (20, 24)22 (20, 26)0.370723 (20, 28)22 (20, 28)23 (20, 28)0.2702SOFA2 (1, 5)2 (0, 14)4 (2, 8)\< 0.00015 (3, 10)3 (2, 5)10 (6, 18)\< 0.0001APACHEII3 (1, 5)3 (1, 5)5 (3, 8)\< 0.00016 (3, 10)5 (2, 7)10.5 (8, 17)\< 0.0001Laboratory findingsLeucocytes- (IQR-10^9^/L)6.1 (4.5, 8.5)5.8 (4.5, 7.8)8.1 (5.0, 13.6)\< 0.00019.4 (5.8, 15.6)7.3 (4.8, 10.2)15.5 (8.9, 21.9)\< 0.0001Distribution, *n* (%) \<4180 (16.8)145 (17.5)35 (14.4)\< 0.000140 (12.3)26 (14.0)14 (10.0)\< 0.0001 4--10707 (66.0)593 (71.6)114 (46.7)133 (40.9)109 (58.6)24 (17.3) \>10185 (17.2)90 (10.9)95 (38.9)152 (46.8)51 (27.4)101 (72.7)Hemoglobin (IQR-g/L)121 (110.0, 131.0)121 (110.0, 130.0)119 (108.0, 131.0)0.1872118 (107.0, 130.0)116.5 (108.0, 129.0)120 (103.0, 133.0)0.5845Distribution, *n* (%) ≤ 9047 (4.4)27 (3.3)20 (8.3)0.000827 (8.5)10 (5.4)17 (12.8)0.0191 \>901021 (95.6)800 (96.7)221 (91.7)292 (91.5)176 (94.6)116 (87.2)Platelets (IQR-10^9^/L)196 (147.0, 253.0)204 (159.0, 260.0)153 (105.0, 216.0)\< 0.0001151.5 (90.5, 208.0)179.5 (140.0, 241.0)90.5 (50.0, 165.0)\< 0.0001Distribution, *n* (%) \<10091 (8.5)34 (4.1)57 (23.5)\< 0.000188 (27.2)15 (8.1)73 (52.9)\< 0.0001 ≥ 100979 (91.5)793 (95.9)186 (76.5)236 (72.8)171 (91.9)65 (47.1)Neutrophils (IQR-10^9^/L)4.2 (2.8, 6.6)3.8 (2.7, 5.7)7.0 (3.6, 13.3)\< 0.00018.3 (4.6, 15.1)5.6 (3.3, 9.1)14.7 (9.9, 20.3)\< 0.0001Distribution, *n* (%) \< 1.865 (6.2)57 (6.9)8 (3.4)\< 0.00018 (2.6)4 (2.3)4 (3.1)\< 0.0001 1.8--6.3703 (66.5)606 (73.5)97 (41.6)109 (35.5)96 (54.5)13 (9.9) \> 6.3289 (27.3)161 (19.6)128 (55.0)190 (61.9)76 (43.2)114 (87.0)Lymphocytes (IQR-10^9^/L)1.2 (0.8, 1.6)1.3 (0.9, 1.7)0.8 (0.5, 1.3)\< 0.00010.8 (0.4, 1.2)1.0 (0.6, 1.4)0.5 (0.3, 0.9)\< 0.0001Distribution, *n* (%) \< 0.8269 (25.6)154 (18.8)115 (49.6)\< 0.0001161 (53.0)67 (38.3)94 (72.9)\< 0.0001 ≥ 0.8783 (74.4)666 (81.2)117 (50.4)143 (47.0)108 (61.7)35 (27.1) CD3 (IQR-/μL)626 (445, 964)710 (470, 1132)522 (367, 636.)\< 0.0001522 (364, 659)562 (427, 793)367 (267, 409)0.0004 CD4 (IQR-/μL)368 (252, 612)416 (283, 730)292 (207, 432)0.0006289 (185, 432)353 (261, 489)211 (145, 248)0.0003 CD8 (IQR-/μL)237 (139, 337)269 (188, 400)155 (114, 252)\<  0.0001155 (116, 252)207 (128, 288)129 (87, 144)0.0044 Prothrombin time (IQR-s)11.4 (10.7, 12.4)11.3 (10.6, 12.2)11.9 (11.1, 13.4)\< 0.000112.4 (11.3, 13.9)11.6 (10.0, 12.6)14 (12.4, 17.5)\< 0.0001Distribution, *n* (%) \<10.5198 (19.1)163 (20.4)35 (14.7)\< 0.000138 (11.9)34 (18.4)4 (3.0)\< 0.0001 10.5--13.5726 (70.0)580 (72.6)146 (61.3)183 (57.4)131 (70.8)52 (38.8) \>13.5113 (10.9)56 (7.0)57 (24.0)98 (30.7)20 (10.8)78 (58.2)Activated-partial thromboplastin time (IQR-s)27.6 (24.3, 32.2)27 (23.9, 31.1)29.9 (25.7, 35.8)\< 0.000130 (25.0, 35.8)29 (24.7, 34.3)33.4 (26.1, 38.9)0.0006Distribution, *n* (%) \<2164 (6.2)47 (5.9)17 (7.3)\< 0.000121 (6.7)14 (7.7)7 (5.4)\< 0.0001 21--37870 (84.2)699 (87.5)171 (73.1)228 (73.1)148 (80.9)80 (62.0) \>3799 (9.6)53 (6.6)46 (19.6)63 (20.1)21 (11.4)42 (32.6)Thrombin time (IQR-s)17.8 (16.7, 20.6)17.7 (16.7, 20.0)18.4 (17.1, 22.4)\< 0.000118.4 (17.1, 21.7)18.3 (17.1, 21.3)18.4 (17.1, 23.0)0.5313Distribution, *n* (%) \<138 (0.8)8 (1.0)0 (0.0)0.00440 (0.0)0 (0.0)0 (0.0)0.4132 13--21782 (75.7)618 (77.4)164 (70.1)224 (72.0)135 (73.8)89 (69.5) \>21243 (23.5)173 (21.6)70 (29.9)87 (28.0)48 (26.2)39 (30.5) D-dimer (IQR-μg/mL)0.8 (0.4, 1.9)0.74 (0.4, 1.4)1.38 (0.5, 9.4)\< 0.00012.21 (0.7, 18.1)0.95 (0.5, 2.8)17.83 (4.5, 56.5)\< 0.0001Distribution, *n* (%) ≤ 0.5322 (31.9)268 (34.5)54 (23.2)\< 0.000155 (17.5)51 (27.9)4 (3.1)\< 0.00010.5--1271 (26.8)227 (29.2)44 (18.9)52 (16.6)43 (23.5)9 (6.9) \>1417 (41.3)282 (36.3)135 (57.9)207 (65.9)89 (48.6)118 (90.0) Total bilirubin (IQR-μmol/L)12.7 (9.9, 17.0)12.1 (9.6, 15.6)16 (11.7, 24.9)\< 0.000116.7 (11.9, 26.4)14.05 (11.0, 18.4)24.9 (16.6, 36.1)\< 0.0001Distribution, *n* (%) ≤ 26954 (91.8)777 (95.8)177 (77.6)\< 0.0001228 (74.5)155 (90.1)73 (54.5)\< 0.0001 \>2685 (8.2)34 (4.2)51 (22.4)78 (25.5)17 (9.9)61 (45.5) Alanine aminotransferase ( (IQR-U/L)41.5 (25.0, 64.0)38 (23.0, 60.0)51 (34.0, 83.0)\< 0.000150 (32.0, 79.0)50 (33.0, 75.0)47 (31.0, 84.0)0.7016Distribution, *n* (%) ≤ 40524 (49.2)436 (52.9)88 (36.5)\< 0.0001123 (38.3)72 (38.7)51 (37.8)0.8654 \>40542 (50.8)389 (47.1)153 (63.5)198 (61.7)114 (61.3)84 (62.2)Aspartate aminotransferase (IQR-U/L)34 (26.0, 49.0)31 (24.0, 44.0)46.5 (34.0, 72.0)\< 0.000148 (35.0, 74.0)40 (31.0, 57.0)58 (44.0, 109.0)\< 0.0001Distribution, *n* (%) ≤ 40679 (63.7)584 (70.9)95 (39.3)\< 0.0001118 (36.5)96 (51.6)22 (16.1)\< 0.0001 \>40387 (36.3)240 (29.1)147 (60.7)205 (63.5)90 (48.4)115 (83.9) Albumin (IQR-g/L)31.7 (28.5, 35.0)32.4 (29.6, 35.7)28.3 (26.0, 31.5)\< 0.000128 (25.5, 30.7)29.5 (27.4, 32.3)26.2 (24.3, 28.3)\< 0.0001Distribution, *n* (%) \<401024 (95.9)780 (94.7)244 (100.0)0.0003326 (100.0)186 (100.0)140 (100.0)1 40--5541 (3.8)41 (5.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) \>553 (0.3)3 (0.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Blood urea nitrogen (IQR-mmol/L)5 (4.0, 6.4)4.8 (3.8, 5.8)6.5 (5.0, 10.2)\< 0.00017.2 (5.4, 11.7)6.1 (4.7, 7.7)13.2 (7.7, 20.3)\< 0.0001Distribution, *n* (%) \<3.181 (7.6)74 (9.0)7 (2.9)\< 0.00017 (2.2)7 (3.8)0 (0.0)\< 0.0001 3.1--8838 (78.6)688 (83.6)150 (61.7)177 (55.5)139 (75.1)38 (28.4) \>8147 (13.8)61 (7.4)86 (35.4)135 (42.3)39 (21.1)96 (71.6) Serum creatinine (IQR-umol/L)72.4 (59.4, 87.2)70.9 (59.0, 83.0)78.8 (62.5, 104.0)\< 0.000179.6 (63.0, 109.8)73.9 (59.5, 91.6)107.8 (69.2, 196.7)\< 0.0001Distribution, *n* (%) \>13365 (6.1)24 (2.9)41 (16.9)\< 0.000160 (18.9)8 (4.3)52 (39.4)\< 0.0001 ≤ 133995 (93.9)794 (97.1)201 (83.1)257 (81.1)177 (95.7)80 (60.6) Creatine kinase (IQR-U/L)76 (50.0, 141.0)71 (49.0, 123.0)123 (54.0, 247.0)\< 0.0001124.5 (55.5, 274.5)89 (48.0, 196.0)240 (101.0, 553.0)\< 0.0001Distribution, *n* (%) \<50235 (24.4)190 (25.2)45 (21.5)\< 0.000153 (19.5)46 (27.7)7 (6.6)\< 0.0001 50--310640 (66.5)517 (68.6)123 (58.9)159 (58.4)102 (61.5)57 (53.8) \>31088 (9.1)47 (6.2)41 (19.6)60 (22.1)18 (10.8)42 (39.6) Creatine kinase isoenzyme MB (IQR-U/L)13 (10.0, 17.0)13 (10.0, 16.0)17 (13.0, 24.0)\< 0.000118 (14.0, 27.0)15 (12.0, 20.0)24 (18.0, 47.0)\< 0.0001Distribution, *n* (%) ≤ 24921 (90.8)747 (95.3)174 (75.7)\< 0.0001213 (70.5)149 (84.7)64 (50.8)\< 0.0001 \>2493 (9.2)37 (4.7)56 (24.3)89 (29.5)27 (15.3)62 (49.2)Serum prealbumin (IQR-g/L)132 (85.0, 191.0)144 (98.0, 201.0)86 (48.0, 132.0)\< 0.000178 (44.5, 122.5)105.5 (70.5, 152.5)48.5 (29.5, 75.0)\< 0.0001Distribution, *n* (%) \<200799 (77.9)588 (74.0)211 (91.3)\< 0.0001286 (92.9)160 (88.9)126 (98.4)0.0013 200--430227 (22.1)207 (26.0)20 (8.7)22 (7.1)20 (11.1)2 (1.6) Serum amyloid protein A (IQR-mg/L)186 (28.9, 272.3)151.6 (20.6, 259.1)242.4 (177.4, 284.0)\< 0.0001246.45 (180.4, 284.0)241.2 (132.4, 284.0)260.1 (188.9, 284.0)0.0103Distribution, *n* (%) ≤ 10150 (16.9)140 (20.0)10 (5.4)\< 0.000111 (4.3)9 (6.0)2 (1.9)0.2075 \>10737 (83.1)560 (80.0)177 (94.6)245 (95.7)142 (94.0)103 (98.1)C-reactive-protein (IQR-mg/L)25.6 (4.9, 79.1)18.4 (3.8, 54.4)86.25 (22.3, 160.0)\< 0.0001102.5 (37.6, 160.0)52.4 (12.1, 103.0)160 (124.2, 177.1)\< 0.0001Distribution, *n* (%) ≤ 6.9287 (30.2)259 (35.4)28 (12.8)\< 0.000131 (10.7)28 (17.4)3 (2.3)\< 0.0001 \>6.9663 (69.8)473 (64.6)190 (87.2)258 (89.3)133 (82.6)125 (97.7)Serum ferritin (IQR-ng/mL)377.72 (133.72, 723.96)344.66 (136.53, 625.70)557.58 (79.26, 1264.47)0.0002618.13 (150.31, 1503.90)647.98 (245.35, 1193.72)616.55 (38.68, 2000.00)0.8666Distribution, *n* (%) \<21.835 (5.0)27 (5.2)8 (4.4)0.09319 (3.6)5 (3.6)4 (3.6)0.1069 21.8-274.6247 (35.1)192 (36.9)55 (30.0)71 (28.5)32 (23.4)39 (34.8) \> 274.6421 (59.9)301 (57.9)120 (65.6)169 (67.9)100 (73.0)69 (61.6)Interleukin-6 (IQR-pg/mL)14.0 (7.8, 398.8)14.6 (7.8, 354.4)13.3 (8.0, 648.4)0.178313.9 (8.4, 660.9)10.5 (7.2, 458.0)31.9 (11.1, 1487.0)\< 0.0001Distribution, *n* (%) ≤ 728 (3.7)20 (3.4)8 (4.6)0.47418 (3.4)5 (4.0)3 (2.8)0.8896 \> 7729 (96.3)563 (96.6)166 (95.4)226 (96.6)121 (96.0)105 (97.2)Radiologic findings Abnormalities, *n* (%) Ground-glass opacity958 (92.3)734 (91.9)224 (93.7)0.3444293 (93.3)176 (94.1)117 (92.1)0.4881 Pulmonary consolidation171 (16.5)106 (13.3)65 (27.2)\< 0.000188 (28.0)49 (26.2)39 (30.7)0.383 Pulmonary interstitial abnormalities646 (62.3)471 (59.0)175 (73.2)\< 0.0001229 (72.9)138 (73.8)91 (71.7)0.6749 Pneumothorax26 (2.5)18 (2.3)8 (3.4)0.343713 (4.1)6 (3.2)7 (5.5)0.3147 Pleural effusion44 (4.2)33 (4.1)11 (4.6)0.750516 (5.1)10 (5.4)6 (4.7)0.8053*SOFA* Sequential Organ Failure Assessment, *APACHEII* Acute Physiology and Chronic Health Evaluation II

Radiologic and laboratory findings {#Sec10}
----------------------------------

A total of 1027 (92.3%) patients had findings of ground-glass opacity on radiographic imaging, 700 (63.0%) patients had interstitial abnormalities. Complex radiologic features such as consolidation (27.2% vs. 13.3%, *p *\< 0.0001) and interstitial changes (73.2% vs. 59.0%, *p *\< 0.0001) and abnormal laboratory results such as hyperleukocytosis (38.9% vs. 10.9%, *p *\< 0.0001), lymphocytopenia (49.6% vs. 18.8%, *p *\< 0.0001), thrombocytopenia (23.5% vs. 4.1%, *p *\< 0.0001) and hypercoagulability (APTT, PT, TT, D-dimer, all *p *\< 0.0001) occurred more in progressors than in non-progressors. There were no significant differences in IL-6 level between the two groups (14.6 pg/ml in non-progressors vs. 13.3 pg/ml in progressors, *p *= 0.178). Abnormal results of laboratory tests (e.g., hyperleukocytosis \[71.7% vs. 27.4%, *p *\< 0.0001\], lymphocytopenia \[72.9% vs. 38.3%, *p *\< 0.0001\], lower CD4 count \[211/μL vs. 353/μL, *p *= 0.0003\], thrombocytopenia \[52.9% vs. 8.1%, *p *\< 0.0001\], hypercoagulability especially elevated D-dimer \[90.1% vs. 48.6%, *p *\< 0.0001\]) were also common in non-survivors (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).

Treatment {#Sec11}
---------

During hospitalization, most (*n* = 987, 82.9%) of patients received oxygen therapy, including nasal cannula (*n* = 792, 66.6%), mask oxygen inhalation (*n* = 27, 2.3%), high-flow nasal cannula (*n* = 60, 5.0%), non-invasive mechanical ventilation (*n* = 62, 5.2%), invasive mechanical ventilation (*n* = 42, 3.5%) and ECMO (*n* = 4, 0.3%, Table [2](#Tab2){ref-type="table"}). 10.2% (*n* = 16) severe patients who suddenly died treated with nasal cannula, 4.5% (*n* = 7) dead severe patients treated with mask oxygen inhalation, 22.9% (*n* = 36) dead severe patients treated with high-flow nasal cannula, 36.9% (*n* = 58) dead severe patients treated with non-invasive mechanical ventilation, 22.9% (*n* = 36) with invasive mechanical ventilation and 2.6% (*n* = 4) with ECMO. Among not severe patients, 259 (99.2%) patients received oxygen therapy in the progression group vs. 640 (76.1%) in the non-progression group (*p *\< 0.0001). Compared with the survivors with severe disease, significantly more non-survivors received non-invasive mechanical ventilation, invasive mechanical ventilation and ECMO (62.4% vs. 4.7%, *p *\< 0.0001) and antiviral treatment (71.8% vs. 43.3% *p *\< 0.0001). More remarkably, there were more non-survivors treated with glucocorticoids (59.8% vs. 39.7%, *p *= 0.0005) among severe patients (Table [4](#Tab4){ref-type="table"}).Table 4Treatments during hospital stay and clinical outcomes of the study patientsNot severe patients at admission (*n* = 1102)Non-progressors (*n* = 841)Progressors (*n* = 261)*p* valueSevere patients (*n* = 349)Survivor (*n* = 192)Non-survivor (*n* = 157)*p* valueTreatments, *n* (%) Antibiotic905 (87.1)690 (84.9)215 (95.1)\< 0.0001287 (95.4)169 (97.1)118 (92.9)0.0865 Antifungal44 (4.2)22 (2.7)22 (9.7)\< 0.000128 (9.3)13 (7.5)15 (11.8)0.2005 Antiviral654 (63.0)501 (61.6)153 (67.7)0.0943180 (59.8)125 (71.8)55 (43.3)\< 0.0001 Glucocorticoids251 (24.2)144 (17.7)107 (47.4)\< 0.0001145 (48.2)69 (39.7)76 (59.8)0.0005 Oxygen therapy, *n* (%)\< 0.0001\< 0.0001  None203 (18.4)201 (23.9)2 (0.8)2 (0.6)2 (1.0)0  Nasal cannula792 (71.9)634 (75.4)158 (60.5)158 (45.3)142 (74.0)16 (10.2)  Mask oxygen17 (1.5)4 (0.5)13 (5.0)23 (6.6)16 (8.3)7 (4.5)  High-flow nasal cannula25 (2.3)1 (0.1)24 (9.2)59 (16.9)23 (12.0)36 (22.9)  Non-invasive mechanical ventilation34 (3.1)0 (0.0)34 (13.0)62 (17.8)4 (2.1)58 (36.9)  Invasive mechanical ventilation28 (2.5)1 (0.1)27 (10.3)41 (11.8)5 (2.6)36 (22.9)  ECMO3 (0.3)0 (0.0)3 (1.2)4 (1.2)0 (0.0)4 (2.6)Outcomes Duration of MV (IQR), days4 (2.0, 8.0)04 (2.0, 8.0)5 (2.0, 8.0)6 (5.0, 9.0)4 (2.0, 8.0)0.1563 Duration of ICU stay (IQR), days006 (3.0, 10.0)6 (3.0, 10.5)7 (4.0, 11.0)5 (2.0, 9.0)0.0522 Duration of in-hospital stay (IQR), days11 (8.00, 15.00)11 (8.0, 14.0)12 (8.0, 16.0)0.002111 (7, 16)14 (10.0, 18.0)8 (4.0, 12.0)\< 0.0001 In-hospital mortality, *n* (%)91 (8.26)0 (0.0)91 (34.9)\< 0.0001157 (45.0)0 (0.0)157 (100.0)\< 0.0001*ECMO* extracorporeal membrane oxygenation, *ICU* intensive care unit, *MV* mechanical ventilation

Nine hundred and seventy-seven (87.7%) patients were treated with empirical antibiotic treatment (*e.g.,* ceftriaxone, moxifloxacin and azithromycin), 681 (61.1%) antiviral therapy (*e.g.,* oseltamivir, ganciclovir, lopinavir/ritonavir, arbidol and interferon), and 289 (25.9%) glucocorticoids. Empirical antibiotic treatment, antiviral therapy and glucocorticoids on admission were also given more commonly to progressors than to non-progressors (Tables [2](#Tab2){ref-type="table"}, [4](#Tab4){ref-type="table"}).

Outcomes {#Sec12}
--------

Two hundred and sixty-one (22.7%) patients without severe condition on admission progressed to severe pneumonia. To analyze the associations between patients' variables and disease development, a multivariate analysis was performed. As shown in Fig. [2](#Fig2){ref-type="fig"}a, independent risk factors for development from not severe to severe disease were presence of pulmonary consolidation (OR 2.59, 95% CI 1.61--4.18, *p *\< 0.001), SOFA score on admission (OR 1.32, 95% CI 1.22--1.43, *p *\< 0.001), lymphocytopenia (OR 1.81, 95% CI 1.13--2.89, *p *= 0.013) and thrombocytopenia (OR 2.39, 95% CI 1.13--5.03, *p *= 0.022). Of note, the deterioration of disease cannot be prevented by glucocorticoids (OR 3.79, 95% CI 2.39--6.01, *p *\< 0.001), but could be prevented by NIV. Independent risk factors for death among all the included patients are shown in Additional file [3](#MOESM3){ref-type="media"}: Table S2.Fig. 2Odds ratios for risk factors associated with in-hospital progression **a** in COVID-19 patients and in-hospital mortality **b** in severe COVID-19 patients. SOFA: Sequential Organ Failure Assessment. IMV: invasive mechanical ventilation. Nasal cannula, glucocorticoids treatment, IMV and antiviral drugs during hospital stay; SOFA score, pulmonary consolidation, leukocytosis, thrombocytopenia and lymphocytopenia, prothrombin time and D-dimer on admission

Among severe patients, 192 survived and 157 died. Figure [3](#Fig3){ref-type="fig"}b shows the survival curve. The risk of death was more than 11 times higher in patients with diabetes than those without diabetes (OR 11.16, 95% CI 1.87--66.57, *p *= 0.008; Fig. [2](#Fig2){ref-type="fig"}b). Other significant independent risk factors for mortality were on admission SOFA score (OR 1.30, 95% CI 1.11--1.53, *p *= 0.001), leukocytopenia (OR 5.10, 95% CI 1.25--20.78, *p *= 0.023), lymphocytopenia (OR 4.44, 95% CI 1.26--15.87, *p *= 0.021), thrombocytopenia (OR 8.37, 95% CI 2.04--34.44, *p *= 0.003) and elevated D-dimer (OR 3.28, 95% CI 1.19--9.04, *p *= 0.021, Fig. [4](#Fig4){ref-type="fig"}). Survival curves of severe patients according to those mortality predictors are shown in Fig. [5](#Fig5){ref-type="fig"}. In a multivariate analysis, antiviral treatment during hospital stay was negatively associated with death (OR 0.17, 95% CI 0.05--0.64, *p *= 0.008) among severe patients with COVID-19. In order to figure out which of them made the major contribution to prolong survival, we conducted survival analysis and found the administration of oseltamivir (HR 0.21, 95% CI 0.10--0.43; *p *\< 0.001) or ganciclovir (HR 0.20, 95% CI 0.07--0.55, *p *\< 0.001) appeared to have reduced the risk of death in severe patients (Fig. [5](#Fig5){ref-type="fig"}).Fig. 3Survival curve in with coronavirus disease. **a** In all enrolled patients. **b** In not severe and severe patients. Nine patients died on admission as a result of unsuccessful rescue effortsFig. 4Cumulative survival curves among severe COVID-19 patients. **a** With DM and without DM; **b** SOFA score \> 5 and SOFA score ≤ 5 on admission; **c** PLT counts on admission; **d** Lym counts on admission; **e** D-dimmer on admission. *DM* diabetes mellitus, *SOFA* Sequential Organ Failure Assessment, *PLT* platelet; *Lym* lymphocyteFig. 5Cumulative survival curve in severe COVID-19 patients with oseltamivir or ganciclovir. **a** Use of ganciclovir during hospital stay reduced the risk of death (hazard ratio, 0.20; 95% CI 0.07--0.55; *p *\< 0.001). **b** Use of oseltamivir during hospital stay reduced the risk of death (hazard ratio, 0.21; 95% CI 0.10--0.43; *p *\< 0.001)

The time interval from disease onset to high-flow nasal cannula, non-invasive mechanical ventilation, invasive mechanical ventilation in survivors with severe disease was 12 day (IQR, 10--17), 11 days (IQR, 9--11), 19 days (IQR 19--41), respectively. However, the time interval from admission to high-flow nasal cannula was 12 days (IQR, 9--17), to non-invasive mechanical ventilation was 16 days (IQR, 11--19), to invasive mechanical ventilation was 18 days (IQR, 13--21) and to ECMO was 22 days (IQR, 22--25) in non-survivors with severe disease. The time interval from admission to high-flow nasal cannula was 1 day (IQR, 0--3), to non-invasive mechanical ventilation was 1 day (IQR, 1--2), to invasive mechanical ventilation was 4 days (IQR, 3--29) in the survivors with severe disease. In the non-survivors with severe disease, the time interval from disease onset to high-flow nasal cannula, non-invasive mechanical ventilation, invasive mechanical ventilation and ECMO was 1 day (IQR, 0--5), 2 days (IQR, 0--5), 6 days (IQR 2--9) and 12 (9--18), respectively (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Time interval between admission and disease onset to respiratory supports. Respiratory supports include high-flow oxygen, non-invasive mechanical ventilation, invasive mechanical ventilation and ECMO. *ECMO* extracorporeal membrane oxygenation

Discussion {#Sec13}
==========

This retrospective cohort study included a very large number of COVID-19 patients reported clinical outcomes and potential risk factors for development from not severe to severe manifestations after admission, as well as those who progressed from severe disease to death. In particular, higher SOFA score, lymphocytopenia on admission were independent risk factors for development to severe manifestations and death. On admission, level of D-dimer greater than 1 μg/L and diabetes were associated with higher risks of in-hospital death in patients with severe COVID-19. Administration of glucocorticoids seemed to increase the risk of deterioration to severe disease after admission. Anti-virus drugs (ganciclovir, oseltamivir) seemed to be associated with less deterioration from not severe to severe disease and from severe disease to death. Moreover, early IMV may be helpful to decrease mortality in severe patients. The risk factors presented in the current study may be helpful for clinicians to early identify patients who will probably progress to severe illness during in-hospital stay. Early interventions could be given to decrease mortality in COVID-19 patients with abnormal biological results. However, the benefits of anti-virus drugs should be interpreted with caution in the absence of data from randomized controlled studies.

COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS) are severe, therefore the respiratory support of COVID-19 patients is essential to decrease mortality. However, there is still controversy regarding the prognosis of COVID-19 after the initiation of mechanical ventilation \[[@CR12]\]. Also it is still necessary to explore that if invasive mechanical ventilation could improve outcome of COVID-19 patients when compared to non-invasive mechanical ventilation \[[@CR13]\]. The present results show that time interval from admission to non-invasive mechanical ventilation in survivors with severe disease was shorter compared with that in non-survivors with severe disease. COVID-19 patients may acquire prognostic benefit from early respiratory support. Since frequent monitoring is needed during process of non-invasive mechanical ventilation, non-invasive mechanical ventilation treatment should be used with caution in resource-limited settings.

The SOFA score is an important marker to indicate the severity of multiple organ dysfunction \[[@CR14]\]. Although the common pathogen to cause sepsis or septic shock is bacteria, virus also causes sepsis particularly in community-acquired pneumonia \[[@CR15]\]. In the present study, higher SOFA score on admission increases the risk of death of severe COVID-19 patients. This is consistent with previous results \[[@CR16]\]. A recent study suggested that the spike protein of SARS-CoV-2 has a strong affinity to human angiotensin-converting enzyme 2 (ACE 2) for host infection \[[@CR17]\]. The SARS-CoV-2 spike protein directly binds with the host cell surface ACE2 receptor facilitating virus entry and replication. ACE2 was expressed in many organs, and is rich in lungs, heart, kidneys and intestine \[[@CR18]\]. Therefore, organ injuries caused by SARS-CoV-2 are extensive and become highly lethal because the virus deregulates an organ protective pathway \[[@CR19]\].

Presence of comorbidities was found to be an independent predictor of poor outcome in our patients. Previous history of cardiovascular diseases (CVD) is independent associated with increased all-cause mortality and in-hospital deterioration COVID-19 patients \[[@CR20]\]. This may be related with enhanced severity of an underlying CVD by occurrence of COVID-19. The prognostic effect of diabetes mellitus has been previously reported in other cohorts of patients with Middle East respiratory syndrome (MERS) \[[@CR21]\] and SARS \[[@CR22]\]. The prognostic relationship between diabetes mellitus and acute viral respiratory infections has been already identified \[[@CR23]\]. Diabetes mellitus has also been identified as a prognostic factor for death in patients with community-acquired pneumonia (CAP) \[[@CR24]\]. This is consistent with the fact that diabetes could predispose patients to be immunologically vulnerable \[[@CR25]\]. The innate immunity is impaired through suppression of the number and function of T cells and neutrophils in diabetic patients \[[@CR26]\]. Secondary infections are common in diabetic patients due to impaired inflammatory and immune biomarker profiles \[[@CR27]\]. The counts of T cells including CD3 T cells, CD4 T cells and CD8 T cells decreased in non-survivors of COVID-19 in the present study. All these findings indirectly argue in favor of the role of diabetes mellitus as a prognostic factor in our patients. However, the direct influence of diabetes mellitus on SARS-Cov-2 infection still needs to be elucidated.

Lymphocytopenia was found as a potential predictor for disease development and death. Thrombocytopenia and leukocytosis also occurred in the severe cases. This may suggest that enhanced inflammation and cytokine storm started from the initial stage. These biological abnormalities were previously observed in patients with severe MERS-CoV-infected patients \[[@CR28]\]. Cytokines are mostly secreted from neutrophils. In patients with MERS, lung injury was correlated with migration of neutrophils and macrophages from peripheral blood to extensive pulmonary \[[@CR29], [@CR30]\]. ARDS caused by cytokine storm was a leading cause of death in patients with Middle East respiratory syndrome \[[@CR31]\]. In our study, only serum IL-6 level has been quantified in some of the COVID-19 patients. However, it is difficult to clarify the influence of cytokine storm on outcome due to missing of IL-6 and other cytokines data.

D-dimer produced by fibrin degradation, reflects the severity of hyper-coagulable state \[[@CR32]\]. Coagulation could be activated to enhance physiological response to several infections \[[@CR33]\]. Microvascular failure and subsequent multiple organ failure could be alleviated through inhibiting activation of coagulation and subsequently improve outcome during systemic hyperinflammation and fulminant sepsis \[[@CR34]\]. D-dimer was previously found to be associated with pneumonia progression \[[@CR35]\] and in-hospital mortality \[[@CR36]\]. The association between elevated D-dimer level with lethal outcome of COVID-19 patients was also reported in a previous study \[[@CR16]\]. ACE 2 is also expressed on vascular endothelial cells \[[@CR37]\]. Thus, one can postulate that coagulation is activated due to high affinity of SARS-CoV-2 with vascular endothelial cells. This can potentially contribute to elevated D-dimer level.

This study has several limitations. First, some laboratory data were missing or not available due to the retrospective data extraction. It should be noted that if important laboratory parameters (such as cardiac troponin, lactic dehydrogenase) were not included in the multivariable analyses, it may cause bias for results. However, we used CK-MB as an alternative indicator of cardiac injury. In addition, we also performed a sensitivity analysis using multiple imputations to account for missing data. The results did not change significantly before or after multiple imputations. Second, benefits of anti-virus drugs on mortality were observed in this study, but we could not further analyze the reason. The mixed virus infection of COVID-19 patients administered with anti-virus drugs should be further explored. Third, although the current study included over 1100 patients from Wuhan Infectious Disease Hospital, still there is a lack of dynamic change for related indicators. Fourth, treatment with methylprednisolone was harmful for not severe patients, however, the dose and duration of methylprednisolone varied, detailed results failed to demonstrate. However, this was the largest cohort study of COVID-19 patients from Wuhan Infectious Disease Hospital until now. A large multi-center cohort study of patients with COVID-19 pneumonia needs to further explore the clinical characteristics and risk factors of the disease.

Conclusions {#Sec14}
===========

In this cohort study, higher SOFA score and lymphocytopenia on admission could predict that not severe patients would develop severe disease in-hospital. Elevated D-dimer on admission, leukocytopenia, thrombocytopenia and diabetes were independent risk factors of in-hospital death in severe patients with COVID-19. These specific characteristics will help clinicians to clarify the progression and the poor prognosis of COVID-19 patients.
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COVID-19

:   Coronavirus disease 2019

SARS-Cov-2

:   Severe acute respiratory syndrome coronavirus 2

SOFA

:   Sequential Organ Failure Assessment

CDC

:   Center for Disease Control and Prevention

ARDS

:   Acute respiratory distress syndrome

WHO

:   World Health Organization

ECMO

:   Extracorporeal membrane oxygenation

CT

:   Computed tomographic

RT-PCR

:   Real-time reverse-transcriptase polymerase chain reaction

NIV

:   Non-invasive mechanical ventilation

IMV

:   Invasive mechanical ventilation

MERS

:   Middle East respiratory syndrome

CAP

:   Community-acquired pneumonia
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